Having trouble accessing articles? Reset your cache.

Boehringer races to catch up in NASH through Yuhan deal

Boehringer is playing catch up in NASH through a preclinical deal with Yuhan that doubles its programs in the indication from one to two and marks its entry into combining therapeutic MOAs -- a strategy the field has pegged as the best bet for attacking the disease.

On Monday, Boehringer Ingelheim GmbH (Ingelheim, Germany) said it is licensing a preclinical fusion protein from

Read the full 622 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers